Immune clues to prevent cancer in Lynch Syndrome
Official title: Immune determinants modulating cancer development in Lynch Syndrome
Funded at Icahn School of Medicine at Mount Sinai · NIH-11457459 · Data updated 2026-11-12
A study exploring how immune signals and shared neoantigens in Lynch Syndrome could help prevent cancer by training the immune system to recognize and fight premalignant lesions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 15, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $912,989 |
| NIH project number | 4UH3CA290517-03 |
| Project ID | NIH-11457459 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Lynch Syndrome or at high risk due to germline MMR deficiencies.
✕Less likely to help
People without Lynch Syndrome or with cancers not related to MMR defects may not benefit.
What this research studies
This project investigates how the body's immune system detects and responds to cancer-related changes in Lynch Syndrome, focusing on neoantigens created by mismatch repair defects. Researchers will look at how frameshift mutations generate shared targets across tumors and how T cells in blood reflect what happens inside tumors. The study also considers vaccination strategies and how early immune activation might stop premalignant polyps from turning into cancer. By combining immune profiling, biomarkers, and potential preventive approaches, the work aims to map paths to prevention in high-risk individuals.
Why it matters
Potential benefit: If successful, the work could lead to new prevention strategies and vaccines for people with Lynch Syndrome.
How similar studies have gone: Prior work has shown that neoantigen targets and T cell responses can be informative for CPI responses; this study builds on that by focusing on prevention in Lynch Syndrome.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Bhardwaj, Nina — Icahn School of Medicine at Mount Sinai
- Study coordinator: Bhardwaj, Nina
Related research
Other NIH-funded projects on the same topics.
-
Personalized, Noninvasive Surveillance for Lynch Syndrome Colorectal Cancer
This project tests a noninvasive fecal test (FIT) alongside colonoscopy to tailor colorectal cancer surveillance for people with Lynch syndrome.
-
Behavioral tool to boost pre-test genetic counseling for Lynch syndrome families
A risk-based program helps families at risk for Lynch syndrome get pre-test counseling more often, so they can learn about genetic testing and cancer prevention.
-
Cancer vaccines for Lynch syndrome in a non-human primate model
A researcher is testing a vaccine approach to help prevent Lynch syndrome–related cancers by training the immune system to recognize cancer-causing changes in the colon using a primate model.
-
Neoantigen vaccine for Lynch syndrome immune interception
A study to test a vaccine that teaches the immune system to recognize cancer-causing mutations in people with Lynch syndrome.
-
Personalized colorectal cancer screening for people with Lynch syndrome
This project aims to find the best colonoscopy schedule for people with Lynch syndrome based on their specific gene.
-
Stool blood testing (FIT) to guide colonoscopy checks for people with Lynch syndrome
This project will test whether a simple stool blood test (FIT) can be used alongside colonoscopies to make cancer screening easier and more personalized for adults with Lynch syndrome.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.